Study wrapper · #905
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
Cannon EJ, Wang W, Norby FL, et al. British journal of clinical pharmacology. 2026.
DOI: 10.1002/bcp.70711PubMed: 42464447
Editor's note
This target-trial emulation matched over 57,000 GLP-1 users and is directly relevant to semaglutide's metabolic profile. The lower diabetes incidence versus liraglutide is a meaningful signal, though the effect emerged only after the first six months and the cardiovascular comparison was underpowered. Observational design means residual confounding cannot be ruled out.
Plain-language abstract
In a large real-world comparison, people prescribed semaglutide for weight management had a lower risk of developing diabetes over one year than those prescribed liraglutide. No difference in cardiovascular events was detected.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026